IVVD
Invivyd·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 1
Consensus Rating "Strong Buy"
Ample Liquidity
High Gross Profit Margin
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About IVVD
Invivyd, Inc.
A biopharmaceutical company that develops antibodies to neutralize SARS-CoV-2, SARS-CoV-1, and pre-emergent coronaviruses
1601 Trapelo Road, Suite 178, Waltham, MA 02451
--
Invivyd, Inc., was incorporated in Delaware on June 3, 2020. The company is a commercial-stage company with a mission to rapidly and permanently deliver antibody-based therapies to protect vulnerable populations from the devastating consequences of the pandemic virus threat, starting with SARS-CoV-2. The company's proprietary INVYMAB platform approach combines state-of-the-art virus surveillance and predictive modeling with advanced antibody engineering. INVYMAB is designed to facilitate the rapid and continuous generation of new monoclonal antibodies (" MABs ") to keep pace with the evolving viral threat.
Earnings Call
Q1/2025
Estimate EPS-0.01
Actual EPS-0.14
Estimate Revenue34.45M
Actual Revenue11.30M
Invivyd's Q1 2025 Earnings Call: Unpacking Contradictions in EUA Strategy, Sales Execution, and Market Approach
May 21,2025 12:46
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
IVVD has released its 2025 Q3 earnings. EPS was reported at -0.06, versus the expected -0.09, beating expectations. The chart below visualizes how IVVD has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
IVVD has released its 2025 Q3 earnings report, with revenue of 13.13M, reflecting a YoY change of 41.17%, and net profit of -10.47M, showing a YoY change of 82.76%. The Sankey diagram below clearly presents IVVD's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
